These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37418588)

  • 1. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
    Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
    Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
    Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
    Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
    Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
    Li L; Miao W; Huang M; Williams P; Wang Y
    Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
    Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
    Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.
    Kanu N; Grönroos E; Martinez P; Burrell RA; Yi Goh X; Bartkova J; Maya-Mendoza A; Mistrík M; Rowan AJ; Patel H; Rabinowitz A; East P; Wilson G; Santos CR; McGranahan N; Gulati S; Gerlinger M; Birkbak NJ; Joshi T; Alexandrov LB; Stratton MR; Powles T; Matthews N; Bates PA; Stewart A; Szallasi Z; Larkin J; Bartek J; Swanton C
    Oncogene; 2015 Nov; 34(46):5699-708. PubMed ID: 25728682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Tong P; Wang J; Castle EP; Stanton ML; Cheville JC; Jonasch E; Brugarolas J; Parker AS
    Mod Pathol; 2016 Jan; 29(1):34-42. PubMed ID: 26516698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETD2 deficiency promotes renal fibrosis through the TGF-β/Smad signalling pathway in the absence of VHL.
    Liu C; Ni L; Li X; Rao H; Feng W; Zhu Y; Zhang W; Ma C; Xu Y; Gui L; Wang Z; Aji R; Xu J; Gao WQ; Li L
    Clin Transl Med; 2023 Nov; 13(11):e1468. PubMed ID: 37933774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
    Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
    Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
    El Khoury LY; Pan X; Hlady RA; Wagner RT; Shaikh S; Wang L; Humphreys MR; Castle EP; Stanton ML; Ho TH; Robertson KD
    Clin Epigenetics; 2023 Apr; 15(1):71. PubMed ID: 37120552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.
    Yang X; Chen R; Chen Y; Zhou Y; Wu C; Li Q; Wu J; Hu WW; Zhao WQ; Wei W; Shi JT; Ji M
    Cancer Sci; 2022 Apr; 113(4):1195-1207. PubMed ID: 35152527
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
    Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
    Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
    Shao IH; Peng PH; Wu HH; Chen JL; Lai JC; Chang JS; Wu HT; Wu KJ; Pang ST; Hsu KW
    Cancer Med; 2023 Apr; 12(8):9788-9801. PubMed ID: 36847128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.